First-in-Class Approved Anti-BCMA Therapy: Belantamab Mafodotin-blmf

Retrieved on: 2020-12-22 18:11:15

Tags for this article:

Click the tags to see associated articles and topics

First-in-Class Approved Anti-BCMA Therapy: Belantamab Mafodotin-blmf. View article details on hiswai:

Excerpt

... inhibiters, immunomodulatory agents, and anti- CD38 monoclonal antibodies. ... Belantamab mafodotin-blmf is an antibody-drug conjugate (ADC).

Article found on: www.pharmacytimes.com